Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study
- PMID: 11003448
- DOI: 10.1034/j.1398-9995.2000.00495.x
Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study
Abstract
Background: Immunotherapy through local routes is thought to be a valuable therapeutic option for respiratory allergy. We investigated the clinical efficacy and immunologic effects of sublingual immunotherapy (SLIT) in asthmatic children with mite-induced respiratory allergy.
Methods: Twenty-four patients (age range 8-15 years), suffering from mild to moderate asthma, with single sensitization to mite allergen, were enrolled. After a 1-year observation phase, patients were randomly allocated to one of two groups, and were given SLIT (sublingual-spit) as drops for 2 years according to a double-blind, placebo-controlled (DBPC) design. Symptoms/medication scores (diary card), visual analog scale, and immunologic parameters (house-dust-mite [HDM]-specific IgE, and total HDM-specific IgG and IgG4) were determined during the observation phase and during the DBPC treatment period.
Results: Twenty-one patients completed the study. At the beginning of the treatment, no difference in environmental allergenic pressure could be shown between the groups. After 2 years of therapy, there was a significant decrease in asthmatic symptoms (P=0.0001) and medication use (P=0.0001) in the active group compared to the placebo group. The visual analog score on overall asthma symptoms improved in the SLIT group (P=0.0001), but not in the placebo group. Nevertheless, the immunologic results did not show significant differences in HDM-specific IgE and total HDM-specific IgG or IgG4 between the active and placebo groups (P = NS). No relevant side-effects were recorded throughout the study.
Conclusions: Our results suggest that treatment for 2 years with SLIT is clinically safe and effective in significantly decreasing respiratory symptoms in children with mild to moderate asthma sensitized to HDM. On the other hand, the lack of changes of the immunologic parameters calls for further investigations with special reference to kinetics and mechanism(s) of action of this mode of treatment.
Similar articles
-
Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures.Pediatr Allergy Immunol. 2007 Feb;18(1):47-57. doi: 10.1111/j.1399-3038.2006.00475.x. Pediatr Allergy Immunol. 2007. PMID: 17295799 Clinical Trial.
-
Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study.Pediatr Allergy Immunol. 2006 Sep;17(6):408-15. doi: 10.1111/j.1399-3038.2006.00443.x. Pediatr Allergy Immunol. 2006. PMID: 16925685 Clinical Trial.
-
Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.Respir Med. 2013 Sep;107(9):1322-9. doi: 10.1016/j.rmed.2013.06.021. Epub 2013 Jul 23. Respir Med. 2013. PMID: 23886432 Clinical Trial.
-
An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.J Allergy Clin Immunol. 2013 Dec;132(6):1322-36. doi: 10.1016/j.jaci.2013.09.004. Epub 2013 Oct 18. J Allergy Clin Immunol. 2013. PMID: 24139829 Review.
-
The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis.Allergy. 2009 Nov;64(11):1570-9. doi: 10.1111/j.1398-9995.2009.02129.x. Epub 2009 Sep 30. Allergy. 2009. PMID: 19796205 Review.
Cited by
-
Sublingual immunotherapy in asthma and rhinoconjunctivitis; systematic review of paediatric literature.Arch Dis Child. 2004 Jul;89(7):620-4. doi: 10.1136/adc.2003.030411. Arch Dis Child. 2004. PMID: 15210490 Free PMC article.
-
Applicability of evidence from previous systematic reviews on immunotherapy in current practice of childhood asthma treatment: a GRADE (Grading of Recommendations Assessment, Development and Evaluation) systematic review.BMJ Open. 2017 Dec 28;7(12):e016326. doi: 10.1136/bmjopen-2017-016326. BMJ Open. 2017. PMID: 29288175 Free PMC article.
-
Sublingual immunotherapy for asthma.Cochrane Database Syst Rev. 2015 Aug 28;2015(8):CD011293. doi: 10.1002/14651858.CD011293.pub2. Cochrane Database Syst Rev. 2015. Update in: Cochrane Database Syst Rev. 2020 Sep 14;9:CD011293. doi: 10.1002/14651858.CD011293.pub3. PMID: 26315994 Free PMC article. Updated.
-
Sublingual Immunotherapy: A Useful Tool for the Allergist in Private Practice.Biomed Res Int. 2016;2016:9323804. doi: 10.1155/2016/9323804. Epub 2016 May 31. Biomed Res Int. 2016. PMID: 27340673 Free PMC article. Review.
-
Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD).Allergo J Int. 2014;23(8):282-319. doi: 10.1007/s40629-014-0032-2. Allergo J Int. 2014. PMID: 26120539 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous